These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 6690204)

  • 41. The effect of Fluosol-DA on oxygen availability in focal cerebral ischemia.
    Sutherland GR; Farrar JK; Peerless SJ
    Stroke; 1984; 15(5):829-35. PubMed ID: 6433517
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Whole body oxygenation using intraperitoneal perfusion of fluorocarbons.
    Faithfull NS; Klein J; van der Zee HT; Salt PJ
    Br J Anaesth; 1984 Aug; 56(8):867-72. PubMed ID: 6430312
    [TBL] [Abstract][Full Text] [Related]  

  • 43. O2 and CO2 solubility of the fluorocarbon emulsion fluosol-DA 20% and O2 and CO2 dissociation curves of blood-fluosol-DA 20% mixtures.
    Grote J; Steuer K; Müller R; Söntgerath C; Zimmer K
    Adv Exp Med Biol; 1985; 191():453-61. PubMed ID: 3938602
    [No Abstract]   [Full Text] [Related]  

  • 44. Effects of dose and scheduling on growth delay of the Lewis lung carcinoma produced by the perfluorochemical emulsion, Fluosol-DA.
    Teicher BA; Rose CM
    Int J Radiat Oncol Biol Phys; 1986 Aug; 12(8):1311-3. PubMed ID: 3093415
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effect of fluosol-DA infusion on pulmonary vascular permeability in the dog lung.
    Hall JE; Ehrhart IC; Hofman WF
    J Trauma; 1986 May; 26(5):432-7. PubMed ID: 3084806
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Effect of Fluosol-DA on infarct morphology and vulnerability to ventricular arrhythmia.
    Kolodgie FD; Dawson AK; Roden DM; Forman MB; Virmani R
    Am Heart J; 1986 Dec; 112(6):1192-201. PubMed ID: 3788766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Phase I/II study of Fluosol-DA and 100% oxygen as an adjuvant to radiation in the treatment of advanced squamous cell tumors of the head and neck.
    Lustig R; McIntosh-Lowe N; Rose C; Haas J; Krasnow S; Spaulding M; Prosnitz L
    Int J Radiat Oncol Biol Phys; 1989 Jun; 16(6):1587-93. PubMed ID: 2722598
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Maternal and fetal effects of exchange transfusion with a red blood cell substitute.
    Cefalo RC; Seeds JW; Proctor HJ; Baker VV
    Am J Obstet Gynecol; 1984 Apr; 148(7):859-67. PubMed ID: 6711627
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of the effect of fluosol DA and dextran 40 on regional cerebral blood flow, infarction size, and mortality in cats with temporary occlusion of the middle cerebral artery.
    Kolluri S; Heros RC; Hedley-Whyte ET; Vonsattel JP; Miller D; Zervas NT
    Surg Neurol; 1986 Jul; 26(1):3-8. PubMed ID: 2424107
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Protective effect of fluosol-DA in acute cerebral ischemia (author's transl)].
    Ishikawa R; Peerless SJ; Hunter IG
    No Shinkei Geka; 1981 Dec; 9(13):1503-8. PubMed ID: 6808409
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical experience with Fluosol-DA.
    Gould SA; Rosen AL; Sehgal LR; Sehgal HL; Moss GS
    Prog Clin Biol Res; 1983; 122():331-42. PubMed ID: 6878375
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Modification of cerebral ischemia with Fluosol.
    Peerless SJ; Nakamura R; Rodriguez-Salazar A; Hunter IG
    Stroke; 1985; 16(1):38-43. PubMed ID: 3966263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The influence of oxygenation on the 19F spin-lattice relaxation rates of fluosol-DA.
    Reid RS; Koch CJ; Castro ME; Lunt JA; Treiber EO; Boisvert DJ; Allen PS
    Phys Med Biol; 1985 Jul; 30(7):677-86. PubMed ID: 4023055
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Development and clinical application of perfluorochemical artificial blood.
    Ohyanagi H; Saitoh Y
    Int J Artif Organs; 1986 Sep; 9(5):363-8. PubMed ID: 3781670
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Role of Fluosol-DA 20% in prehospital resuscitation.
    Elliott LA; Ledgerwood AM; Lucas CE; McCoy LE; McGonigal M; Sullivan MW
    Crit Care Med; 1989 Feb; 17(2):166-72. PubMed ID: 2914450
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hemodynamic profile of adverse clinical reactions to Fluosol-DA 20%.
    Tremper KK; Vercellotti GM; Hammerschmidt DE
    Crit Care Med; 1984 May; 12(5):428-31. PubMed ID: 6713912
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Limitation of myocardial reperfusion injury by intravenous perfluorochemicals. Role of neutrophil activation.
    Bajaj AK; Cobb MA; Virmani R; Gay JC; Light RT; Forman MB
    Circulation; 1989 Mar; 79(3):645-56. PubMed ID: 2537160
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effects of fetal exchange transfusion with a red blood cell substitute.
    Ambrose A; Cefalo RC; Bowes WA
    Am J Obstet Gynecol; 1986 Mar; 154(3):667-74. PubMed ID: 3082209
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Initial results of a clinical trial of Fluosol-DA 20 percent in acute cerebral ischemia.
    Swann KW; Ropper AH; Zervas NT
    Prog Clin Biol Res; 1983; 122():399-404. PubMed ID: 6348787
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Critical oxygen delivery levels during shock following normoxic and hyperoxic haemodilution with fluorocarbons or dextran.
    Faithfull NS; Cain SM
    Adv Exp Med Biol; 1987; 215():79-87. PubMed ID: 2445179
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.